# Arvinas, Inc.: financial statements, quarterly

ARVN · Nasdaq · CIK 1655759 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arvn.md) · [Financials](/companies/arvn/financials.md) · [Filings](/companies/arvn/filings.md) · [Insiders](/companies/arvn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arvn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.6](/filings/0001655759-24-000131.md) | [(43.1) d](/filings/0001628280-26-011226.md) | [25.3](/filings/0001655759-25-000085.md) | [76.5](/filings/0001655759-25-000139.md) | [102](/filings/0001628280-25-049527.md) | [59.2 d](/filings/0001628280-26-011226.md) | [189](/filings/0001628280-26-033669.md) | [22.4](/filings/0001628280-26-052554.md) | [41.9](/filings/0001628280-25-049527.md) | [9.5 d](/filings/0001628280-26-011226.md) | [15.6](/filings/0001628280-26-033669.md) | [250](/filings/0001628280-26-052554.md) |
| Research and development | $m | [85.9](/filings/0001655759-24-000131.md) | [95.2 d](/filings/0001628280-26-011226.md) | [84.3](/filings/0001655759-25-000085.md) | [93.7](/filings/0001655759-25-000139.md) | [86.9](/filings/0001628280-25-049527.md) | [83.3 d](/filings/0001628280-26-011226.md) | [90.8](/filings/0001628280-26-033669.md) | [68.6](/filings/0001628280-26-052554.md) | [64.7](/filings/0001628280-25-049527.md) | [61.1 d](/filings/0001628280-26-011226.md) | [60.3](/filings/0001628280-26-033669.md) | [52.6](/filings/0001628280-26-052554.md) |
| Operating income | $m | [(73.9)](/filings/0001655759-24-000131.md) | [(165) d](/filings/0001628280-26-011226.md) | [(83.3)](/filings/0001655759-25-000085.md) | [(48.5)](/filings/0001655759-25-000139.md) | [(60.3)](/filings/0001628280-25-049527.md) | [(58.2) d](/filings/0001628280-26-011226.md) | [71.4](/filings/0001628280-26-033669.md) | [(71.5)](/filings/0001628280-26-052554.md) | [(43.8)](/filings/0001628280-25-049527.md) | [(74.6) d](/filings/0001628280-26-011226.md) | [(63.8)](/filings/0001628280-26-033669.md) | [164](/filings/0001628280-26-052554.md) |
| Interest expense | $m | [0.0](/filings/0001655759-24-000131.md) | [0.0 d](/filings/0001655759-25-000016.md) | [0.0](/filings/0001655759-25-000085.md) | [0.0](/filings/0001655759-25-000139.md) | [0.0](/filings/0001655759-24-000131.md) | [0.0 d](/filings/0001655759-25-000016.md) | [0.0](/filings/0001655759-25-000085.md) | [0.0](/filings/0001655759-25-000139.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001655759-24-000131.md) | [1.6 d](/filings/0001628280-26-011226.md) | [0.1](/filings/0001655759-25-000085.md) | [0.2](/filings/0001655759-25-000139.md) | [0.6](/filings/0001628280-25-049527.md) | [(0.4) d](/filings/0001628280-26-011226.md) | [0.2](/filings/0001628280-26-033669.md) | [(0.3)](/filings/0001628280-26-052554.md) | [0.3](/filings/0001628280-25-049527.md) | [0.2 d](/filings/0001628280-26-011226.md) | [0.1](/filings/0001628280-26-033669.md) | [0.2](/filings/0001628280-26-052554.md) |
| Net income | $m | [(64.0)](/filings/0001655759-24-000131.md) | [(155) d](/filings/0001628280-26-011226.md) | [(69.4)](/filings/0001655759-25-000085.md) | [(35.2)](/filings/0001655759-25-000139.md) | [(49.2)](/filings/0001628280-25-049527.md) | [(45.1) d](/filings/0001628280-26-011226.md) | [82.9](/filings/0001628280-26-033669.md) | [(61.2)](/filings/0001628280-26-052554.md) | [(35.1)](/filings/0001628280-25-049527.md) | [(67.4) d](/filings/0001628280-26-011226.md) | [(57.6)](/filings/0001628280-26-033669.md) | [169](/filings/0001628280-26-052554.md) |
| Diluted EPS | $ per share | [(1.18)](/filings/0001655759-24-000131.md) | not reported | [(0.97)](/filings/0001655759-25-000085.md) | [(0.49)](/filings/0001655759-25-000139.md) | [(0.68)](/filings/0001628280-25-049527.md) | not reported | [1.14](/filings/0001628280-26-033669.md) | [(0.84)](/filings/0001628280-26-052554.md) | [(0.48)](/filings/0001628280-25-049527.md) | not reported | [(0.90)](/filings/0001628280-26-033669.md) | [2.58](/filings/0001628280-26-052554.md) |
| Basic EPS | $ per share | [(1.18)](/filings/0001655759-24-000131.md) | not reported | [(0.97)](/filings/0001655759-25-000085.md) | [(0.49)](/filings/0001655759-25-000139.md) | [(0.68)](/filings/0001628280-25-049527.md) | not reported | [1.14](/filings/0001628280-26-033669.md) | [(0.84)](/filings/0001628280-26-052554.md) | [(0.48)](/filings/0001628280-25-049527.md) | not reported | [(0.90)](/filings/0001628280-26-033669.md) | [2.61](/filings/0001628280-26-052554.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [114](/filings/0001655759-24-000131.md) | [312](/filings/0001628280-26-011226.md) | [88.0](/filings/0001655759-25-000085.md) | [155](/filings/0001655759-25-000139.md) | [85.2](/filings/0001655759-24-000131.md) | [101](/filings/0001628280-26-011226.md) | [81.0](/filings/0001655759-25-000085.md) | [115](/filings/0001655759-25-000139.md) | [102](/filings/0001628280-25-049527.md) | [143](/filings/0001628280-26-052554.md) | [87.3](/filings/0001628280-26-033669.md) | [94.3](/filings/0001628280-26-052554.md) |
| Current assets | $m | [1,033](/filings/0001655759-23-000093.md) | [1,280](/filings/0001655759-25-000016.md) | [1,190](/filings/0001655759-24-000060.md) | [1,257](/filings/0001655759-24-000118.md) | [1,150](/filings/0001655759-24-000131.md) | [1,067](/filings/0001628280-26-011226.md) | [980](/filings/0001655759-25-000085.md) | [890](/filings/0001655759-25-000139.md) | [826](/filings/0001628280-25-049527.md) | [701](/filings/0001628280-26-052554.md) | [631](/filings/0001628280-26-033669.md) | [652](/filings/0001628280-26-052554.md) |
| Total assets | $m | [1,058](/filings/0001655759-23-000093.md) | [1,305](/filings/0001655759-25-000016.md) | [1,213](/filings/0001655759-24-000060.md) | [1,280](/filings/0001655759-24-000118.md) | [1,167](/filings/0001655759-24-000131.md) | [1,091](/filings/0001628280-26-011226.md) | [1,001](/filings/0001655759-25-000085.md) | [909](/filings/0001655759-25-000139.md) | [844](/filings/0001628280-25-049527.md) | [718](/filings/0001628280-26-052554.md) | [648](/filings/0001628280-26-033669.md) | [675](/filings/0001628280-26-052554.md) |
| Current liabilities | $m | [317](/filings/0001655759-23-000093.md) | [257](/filings/0001655759-25-000016.md) | [241](/filings/0001655759-24-000060.md) | [347](/filings/0001655759-24-000118.md) | [276](/filings/0001655759-24-000131.md) | [230](/filings/0001628280-26-011226.md) | [214](/filings/0001655759-25-000085.md) | [158](/filings/0001655759-25-000139.md) | [145](/filings/0001628280-25-049527.md) | [143](/filings/0001628280-26-052554.md) | [116](/filings/0001628280-26-033669.md) | [82.5](/filings/0001628280-26-052554.md) |
| Total liabilities | $m | [601](/filings/0001655759-23-000093.md) | [645](/filings/0001655759-25-000016.md) | [603](/filings/0001655759-24-000060.md) | [679](/filings/0001655759-24-000118.md) | [581](/filings/0001655759-24-000131.md) | [530](/filings/0001628280-26-011226.md) | [341](/filings/0001655759-25-000085.md) | [300](/filings/0001655759-25-000139.md) | [280](/filings/0001628280-25-049527.md) | [284](/filings/0001628280-26-052554.md) | [261](/filings/0001628280-26-033669.md) | [113](/filings/0001628280-26-052554.md) |
| Long-term debt | $m | [0.8](/filings/0001655759-23-000093.md) | [0.8](/filings/0001655759-25-000016.md) | [0.7](/filings/0001655759-24-000060.md) | [0.7](/filings/0001655759-24-000118.md) | [0.6](/filings/0001655759-24-000131.md) | [0.6](/filings/0001628280-26-011226.md) | [0.5](/filings/0001655759-25-000085.md) | [0.5](/filings/0001655759-25-000139.md) | [0.4](/filings/0001628280-25-049527.md) | [0.4](/filings/0001628280-26-052554.md) | [0.3](/filings/0001628280-26-033669.md) | [0.3](/filings/0001628280-26-052554.md) |
| Current portion of debt | $m | [0.2](/filings/0001655759-23-000093.md) | [0.2](/filings/0001655759-25-000016.md) | [0.2](/filings/0001655759-24-000060.md) | [0.2](/filings/0001655759-24-000118.md) | [0.2](/filings/0001655759-24-000131.md) | [0.2](/filings/0001628280-26-011226.md) | [0.2](/filings/0001655759-25-000085.md) | [0.2](/filings/0001655759-25-000139.md) | [0.2](/filings/0001628280-25-049527.md) | [0.2](/filings/0001628280-26-052554.md) | [0.2](/filings/0001628280-26-033669.md) | [0.2](/filings/0001628280-26-052554.md) |
| Shareholders' equity | $m | [457](/filings/0001655759-24-000131.md) | [660](/filings/0001628280-26-011226.md) | [610](/filings/0001655759-25-000139.md) | [600](/filings/0001628280-25-049527.md) | [586](/filings/0001628280-25-049527.md) | [562](/filings/0001628280-26-052554.md) | [660](/filings/0001628280-26-052554.md) | [609](/filings/0001628280-26-052554.md) | [564](/filings/0001628280-25-049527.md) | [434](/filings/0001628280-26-052554.md) | [387](/filings/0001628280-26-052554.md) | [562](/filings/0001628280-26-052554.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(84.8) d](/filings/0001655759-24-000131.md) | [(83.1) d](/filings/0001628280-26-011226.md) | [(97.5)](/filings/0001655759-25-000085.md) | [50.3 d](/filings/0001655759-25-000139.md) | [(128) d](/filings/0001628280-25-049527.md) | [(84.1) d](/filings/0001628280-26-011226.md) | [(88.9)](/filings/0001628280-26-033669.md) | [(95.4) d](/filings/0001628280-26-052554.md) | [(59.1) d](/filings/0001628280-25-049527.md) | [(30.4) d](/filings/0001628280-26-011226.md) | [(69.2)](/filings/0001628280-26-033669.md) | [(48.3) d](/filings/0001628280-26-052554.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001655759-24-000131.md) | [0.1 d](/filings/0001628280-26-011226.md) | [0.1](/filings/0001655759-25-000085.md) | [0.7 d](/filings/0001655759-25-000139.md) | [0.7 d](/filings/0001628280-25-049527.md) | [0.3 d](/filings/0001628280-26-011226.md) | [0.4](/filings/0001628280-26-033669.md) | [1.2 d](/filings/0001628280-26-052554.md) | [0.1 d](/filings/0001628280-25-049527.md) | [0.2 d](/filings/0001628280-26-011226.md) | [1.3](/filings/0001628280-26-033669.md) | [0.2 d](/filings/0001628280-26-052554.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001628280-26-011226.md) | not reported | not reported | not reported | [74.1 d](/filings/0001628280-26-011226.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [53.2](/filings/0001655759-23-000093.md) | [53.3](/filings/0001655759-24-000060.md) | [53.4](/filings/0001655759-24-000118.md) | [54.1](/filings/0001655759-24-000131.md) | [71.7](/filings/0001655759-25-000085.md) | [71.9](/filings/0001655759-25-000139.md) | [72.1](/filings/0001628280-25-049527.md) | [72.7](/filings/0001628280-26-033669.md) | [73.0](/filings/0001628280-26-052554.md) | [73.2](/filings/0001628280-25-049527.md) | [64.0](/filings/0001628280-26-033669.md) | [65.7](/filings/0001628280-26-052554.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 65,386,191 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052554.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.